163 related articles for article (PubMed ID: 31160353)
1. A case study of a long-term glioblastoma survivor with unmethylated
Jue TR; Olafson LR; Siddell AH; Rapkins RW; Ng B; Yin JXM; Lu VM; Chung SA; Whittaker SP; Davies M; Fairhall JM; Hovey EJ; McDonald KL
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160353
[TBL] [Abstract][Full Text] [Related]
2. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
[TBL] [Abstract][Full Text] [Related]
3. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
[TBL] [Abstract][Full Text] [Related]
5. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.
Haraldsdottir S; Hampel H; Tomsic J; Frankel WL; Pearlman R; de la Chapelle A; Pritchard CC
Gastroenterology; 2014 Dec; 147(6):1308-1316.e1. PubMed ID: 25194673
[TBL] [Abstract][Full Text] [Related]
6. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
7. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
8. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Vaubel RA; Tian S; Remonde D; Schroeder MA; Mladek AC; Kitange GJ; Caron A; Kollmeyer TM; Grove R; Peng S; Carlson BL; Ma DJ; Sarkar G; Evers L; Decker PA; Yan H; Dhruv HD; Berens ME; Wang Q; Marin BM; Klee EW; Califano A; LaChance DH; Eckel-Passow JE; Verhaak RG; Sulman EP; Burns TC; Meyer FB; O'Neill BP; Tran NL; Giannini C; Jenkins RB; Parney IF; Sarkaria JN
Clin Cancer Res; 2020 Mar; 26(5):1094-1104. PubMed ID: 31852831
[TBL] [Abstract][Full Text] [Related]
9. Germline Biallelic Mismatch Repair Deficiency in Childhood Glioblastoma and Implications for Clinical Management.
Mishra AK; Achari RB; Zameer L; Achari G; Gehani A; Roy P; Sudhaman S; Bianchi V; Edwards M; Sen S; Sukumaran RK; Bhattacharyya A; Tabori U; Das A
Neurol India; 2022; 70(2):772-774. PubMed ID: 35532657
[TBL] [Abstract][Full Text] [Related]
10. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
Sa JK; Choi SW; Zhao J; Lee Y; Zhang J; Kong DS; Choi JW; Seol HJ; Lee JI; Iavarone A; Rabadan R; Nam DH
Int J Cancer; 2019 Jun; 144(12):3023-3030. PubMed ID: 30536544
[TBL] [Abstract][Full Text] [Related]
11. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
[TBL] [Abstract][Full Text] [Related]
12. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract][Full Text] [Related]
13.
Choi HJ; Choi SH; You SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park CK; Park SH
AJNR Am J Neuroradiol; 2021 May; 42(5):853-860. PubMed ID: 33632732
[TBL] [Abstract][Full Text] [Related]
14. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
15. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
[TBL] [Abstract][Full Text] [Related]
16. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.
Cho YA; Kim D; Lee B; Shim JH; Suh YL
J Neurooncol; 2021 May; 153(1):43-53. PubMed ID: 33864561
[TBL] [Abstract][Full Text] [Related]
17. Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Kim H; Lim KY; Park JW; Kang J; Won JK; Lee K; Shim Y; Park CK; Kim SK; Choi SH; Kim TM; Yun H; Park SH
Lab Invest; 2022 Feb; 102(2):160-171. PubMed ID: 34848827
[TBL] [Abstract][Full Text] [Related]
18. Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity.
Lai PC; Chen SH; Yang SH; Cheng CC; Chiu TH; Huang YT
Pediatr Neonatol; 2012 Jun; 53(3):199-204. PubMed ID: 22770110
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
20. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
